IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.878
SA - Sud America 441
NA - Nord America 269
EU - Europa 107
AF - Africa 40
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.736
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 2.154
SG - Singapore 1.479
BR - Brasile 385
US - Stati Uniti d'America 208
VN - Vietnam 85
IN - India 39
MX - Messico 37
BD - Bangladesh 35
IT - Italia 32
CN - Cina 29
AR - Argentina 20
GB - Regno Unito 19
ZA - Sudafrica 14
CA - Canada 13
DE - Germania 11
EC - Ecuador 11
IQ - Iraq 10
NL - Olanda 9
PL - Polonia 9
CO - Colombia 8
RU - Federazione Russa 7
UZ - Uzbekistan 7
CL - Cile 6
JP - Giappone 6
MA - Marocco 6
TN - Tunisia 6
TR - Turchia 6
ID - Indonesia 5
UA - Ucraina 5
EG - Egitto 4
ET - Etiopia 4
JM - Giamaica 4
SA - Arabia Saudita 4
UY - Uruguay 4
BB - Barbados 3
DZ - Algeria 3
KE - Kenya 3
PK - Pakistan 3
PY - Paraguay 3
AT - Austria 2
ES - Italia 2
KG - Kirghizistan 2
LT - Lituania 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
SE - Svezia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
FR - Francia 1
GE - Georgia 1
GY - Guiana 1
IE - Irlanda 1
IL - Israele 1
JO - Giordania 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.736
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.154
Singapore 172
Ho Chi Minh City 28
São Paulo 27
Beijing 26
Hanoi 25
Mexico City 20
Ashburn 19
Los Angeles 15
Mumbai 12
Dhaka 10
Rio de Janeiro 10
San Pietro Vernotico 9
Warsaw 9
Goiânia 6
Porto Alegre 6
Baghdad 5
Boardman 5
Brasília 5
Brooklyn 5
Johannesburg 5
New Delhi 5
Salvador 5
Santiago 5
Tashkent 5
Thái Nguyên 5
Tokyo 5
Addis Ababa 4
Biên Hòa 4
Bologna 4
Caxias do Sul 4
Chennai 4
Chiarano 4
Cotia 4
Franca 4
Guayaquil 4
Juiz de Fora 4
Montreal 4
Orlando 4
Piracicaba 4
Querétaro 4
Ribeirão Preto 4
Santo André 4
São Bernardo do Campo 4
Uberlândia 4
Asunción 3
Atlanta 3
Belo Horizonte 3
Bridgetown 3
Cape Town 3
Casablanca 3
Council Bluffs 3
Curitiba 3
Da Nang 3
Fortaleza 3
Kingston 3
Manaus 3
Milan 3
Nairobi 3
New York 3
Orem 3
Phoenix 3
Pune 3
Ribeirão das Neves 3
Rio Grande 3
Sumaré 3
Tunis 3
Adamantina 2
Alegrete 2
Alvorada 2
Ankara 2
Aracaju 2
Barretos 2
Benito Juarez 2
Bragança Paulista 2
Brumadinho 2
Cairo 2
Camaçari 2
Campinas 2
Campo Largo 2
Canoas 2
Chapecó 2
Charlotte 2
Chicago 2
Concordia 2
Cuenca 2
Cuiabá 2
Dourados 2
Erbil 2
Feira de Santana 2
Florianópolis 2
Fort Lauderdale 2
Foz do Iguaçu 2
Frankfurt am Main 2
Haiphong 2
Ipatinga 2
Itajubá 2
Itu 2
Jandaia do Sul 2
Joinville 2
Totale 2.807
Salva come PNG Salva come JPEG
Nome #
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 99
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 94
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 94
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity 93
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 81
Prevention and therapy of neutropenia in elderly patients 78
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 72
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 70
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 69
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 55
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 54
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 52
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 50
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 49
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 49
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 48
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 48
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 47
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 46
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 46
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 44
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 43
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases 43
Adjuvant concomitant chemotherapy in pancreatic cancer. 42
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 41
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 41
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 40
Anticancer drug delivery with nanoparticles 40
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients 40
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 40
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 40
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 38
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 38
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 37
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 37
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 37
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 36
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 36
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 36
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 36
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization 36
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 35
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 35
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer 35
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 34
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 33
Cell-free DNA as a diagnostic marker for cancer: current insights 33
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 33
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 32
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 32
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 32
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 32
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 32
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry 32
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. 32
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 32
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 31
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 30
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 30
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 30
Germ cell tumours of the testis 30
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 30
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 30
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 30
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 29
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 28
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 28
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 28
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 28
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 27
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 27
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 27
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 27
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 26
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 26
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 25
Consider quality of life to improve quality of cancer guidelines 25
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 25
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 25
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 25
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 25
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party 25
Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 25
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 24
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 24
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 24
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 24
Immunotherapy for prostate cancer: Where we are headed 23
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 23
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience 23
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 23
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 22
Early use of abiraterone and radium-223 in metastatic prostate cancer 22
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 22
The prognostic value of pain in castration-sensitive prostate cancer 22
Sexual functions after high-dose chemotherapy in survivors of germ cell tumors 22
Circulating tumor cells in newly diagnosed inflammatory breast cancer 21
Circulating tumor cells in metastatic inflammatory breast cancer 21
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 20
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 20
Totale 3.731
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.898 0 0 0 0 0 0 315 6 1.345 704 213 315
2025/20262.135 635 795 274 197 129 105 0 0 0 0 0 0
Totale 5.033